Riaan Van Dyk is the general manager of Kemin Biologics, which will manufacture and market Aptimmune's proprietary Barricade™ swine vaccine technology and products outside the U.S. as part of the Kemin-Aptimmune partnership the companies formed in 2018. Prior to this role, he served as vice president of marketing and strategy for Kemin Industries Worldwide.
Van Dyk has worked in some of the fastest-growing health markets in the world. He has 20 years of experience creating and driving core brand strategies to increase market share in the pharmaceutical/life sciences industries. Van Dyk served as the marketing director for Elanco (a division of Eli Lilly) in Asia Pacific and South Africa, where he led a team of marketing and technical managers, pricing consultants and product launch leaders.
A significant part of his career has also focused on the animal health industry, with a unique and valuable overlay of experience from six years of employment in the Asian market.
Van Dyk holds master’s degrees in business and science, as well as multiple bachelor’s degrees in animal nutrition and science. He is fluent in both English and Afrikaans.